Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer

Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer

<p>Abstract</p> <p>Alpha-methylacyl-CoA racemase (AMACR) is an enzyme playing an important role in the beta-oxidation of branched-chain fatty acids and fatty acid derivatives. High expression levels of AMACR have been described in various cancers, including prostate cancer, colorec...

Full description

Bibliographic Details
Main Authors: Masumori Naoya, Sato Eiji, Kitamura Hiroshi, Hirohashi Yoshihiko, Torigoe Toshihiko, Honma Ichiya, Tamura Yasuaki, Tsukamoto Taiji, Sato Noriyuki
Format: Article
Language:English
Published: BMC 2009-12-01
Series:Journal of Translational Medicine
Online Access:http://www.translational-medicine.com/content/7/1/103

Internet

http://www.translational-medicine.com/content/7/1/103

Similar Items